Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;27(6):304-309.
doi: 10.1007/s12471-019-1250-5.

Large next-generation sequencing gene panels in genetic heart disease: yield of pathogenic variants and variants of unknown significance

F H M van Lint  1 , O R F Mook  1 , M Alders  1 , H Bikker  1 , R H Lekanne Dit Deprez  1 , I Christiaans  2   3
Affiliations

Large next-generation sequencing gene panels in genetic heart disease: yield of pathogenic variants and variants of unknown significance

F H M van Lint et al. Neth Heart J. 2019 Jun.

Abstract

Background: Genetic heterogeneity is common in inherited cardiac diseases. Next-generation sequencing gene panels are therefore suitable for genetic diagnosis. We describe the results of implementation of cardiomyopathy and arrhythmia gene panels in clinical care.

Methods: We present detection rates for variants with unknown (class 3), likely (class 4), and certain (class 5) pathogenicity in cardiogenetic gene panels since their introduction into diagnostics.

Results: In 936 patients tested on the arrhythmia panel, likely pathogenic and pathogenic variants were detected in 8.8% (4.6% class 5; 4.2% class 4), and one or multiple class 3 variants in 34.8%. In 1970 patients tested on the cardiomyopathy panel, likely pathogenic and pathogenic variants were detected in 19.8% (12.0% class 5; 7.9% class 4), and one or multiple class 3 variants in 40.8%. Detection rates of all different classes of variants increased with the increasing number of genes on the cardiomyopathy gene panel. Multiple variants were detected in 11.7% and 28.5% of patients on the arrhythmia and cardiomyopathy panels respectively. In more recent larger versions of the cardiomyopathy gene panel the detection rate of likely pathogenic and pathogenic variants only slightly increased, but was associated with a large increase of class 3 variants.

Conclusion: Overall detection rates (class 3, 4, and 5 variants) in a diagnostic setting are 44% and 61% for the arrhythmia and cardiomyopathy gene panel respectively, with only a small minority of likely pathogenic and pathogenic variants (8.8% and 19.8% respectively). Larger gene panels can increase the detection rate of likely pathogenic and pathogenic variants, but mainly increase the frequency of variants of unknown pathogenicity.

Keywords: Cardiogenetic; Detection rate; Gene panel; Next-generation sequencing; Variants of unknown significance.

PubMed Disclaimer

References

    1. Mogensen J, van Tintelen JP, Fokstuen S, et al. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. Eur Heart J. 2015;36:1367–1370. doi: 10.1093/eurheartj/ehv122. - DOI - PubMed
    1. Mook OR, Haagmans MA, Soucy JF, et al. Targeted sequence capture and GS-FLX Titanium sequencing of 23 hypertrophic and dilated cardiomyopathy genes: implementation into diagnostics. J. Med. Genet. 2013;50:614–626. doi: 10.1136/jmedgenet-2012-101231. - DOI - PMC - PubMed
    1. Matthijs G, Souche E, Alders M, et al. Guidelines for diagnostic next-generation sequencing. Eur J Hum Genet. 2016;24:2–5. doi: 10.1038/ejhg.2015.226. - DOI - PMC - PubMed
    1. Nishio Y, Makiyama T, Itoh H, et al. D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J Am Coll Cardiol. 2009;54:812–819. doi: 10.1016/j.jacc.2009.06.005. - DOI - PubMed
    1. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) Heart Rhythm. 2011;8:1308–1339. doi: 10.1016/j.hrthm.2011.05.020. - DOI - PubMed